A study published Feb 13th in Cell provides an unprecedented look at the dozens of molecular steps that occur to bring about endometrial cancer, commonly known as uterine cancer. The study offers insights about how physicians might be able to better identify which patients will need aggressive treatment and which won’t, and offers clues about why a common treatment is not effective with some patients.

The addition of 367 new pathology slides and 51 new pathology subjects for lung squamous cell carcinoma is now available on the TCIA CPTAC Pathology Portal. Additional imaging data is also available for 10 cancer types including cutaneous melanoma, clear cell renal cell carcinoma, head & neck squamous cell carcinoma, glioblastoma multiforme, lung adenocarcinoma, ductal carcinoma, corpus endometrial carcinoma, acute myeloid leukemia (AML), cutaneous melanoma, and sarcoma tumor types.

The Office of Cancer Clinical Proteomics Research (OCCPR) cares what you think about the Clinical Proteomic Tumor Analysis Consortium (CPTAC) program and all its offerings! Working with Clarivate Analytics to conduct a survey, we wanted to determine the effect of the CPTAC program on the proteogenomic research community.  The evaluation provided the NCI with an objective, third-party assessment of CPTAC program implementation.

Visualizing gene and protein expression from comprehensive genomics and proteomics (mass spectrometry generated) data is beneficial for researchers but often difficult to achieve. Researchers from the Mount Sinai PGDAC team within the CPTAC program have developed a new interactive data tool to query genes and proteins of interest in a visual format.

Using a single-needle biopsy and new technology for tumor diagnosis developed by Baylor College of Medicine and the Broad Institute of MIT and Harvard, researchers have been able to provide a more detailed and wider window into cancer biology, tumor type and the mechanisms of response and resistance to therapy than with conventional approaches.

The Genomic Data Commons (GDC) data release 22 is now available and includes data from the CPTAC Glioblastoma Multiforme Discovery Study. 

The Clinical Proteomic Tumor Analysis Consortium (CPTAC), sponsored by the National Cancer Institute’s (NCI) Office of Cancer Clinical Proteomics Research (OCCPR) and managed by The Frederick National Laboratory for Cancer Research (FNLCR), is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteomics, genomics and proteogenomics.  

Glioblastoma Multiforme Discovery Study proteomic and phosphoproteomic data previously available only on thte CPTAC Data Portal is now available on the Proteomic Data Com

TCIA has released its quarterly update for CPTAC radiology data with 44 new radiology cases!  These cases span cutaneous melanoma, glioblastoma multiforme, head & neck squamous cell carcinoma, lung squamous cell carcinoma, lung adenocarcinoma, pancreatic ductal adenocarcinoma and sarcoma tumor tissue types.  In addition, the TCIA monthly histopathology report lists the addition of 10 new pathology slides

Antibodies are among the most commonly used tools in the biological sciences - put to work in many experiments to identify and isolate other molecules.  NCI’s Antibody Program has developed more than 500 available antibodies that have been designed and optimized, with the vast majority developed as fit-for-purpose reagents.